Dr Daniel Hodson talks about the DIRECT clinical trial for diffuse large B-cell lymphoma (DLBCL). DIRECT focuses on both stratifying the different sub-types of DLBCL in order to provide personalised treatment for patients and on prioritising patients who do not respond well to current standard of care in order to introduce alternative treatments to their care plan.
Daniel is a Principal Investigator and Honorary Consultant at the Department of Haematology, University of Cambridge, UK and is Chief Investigator for the DIRECT clinical trial.
